Beam Therapeutics GAAP EPS of -$1.17 misses by $0.02, revenue of $14.27M beats by $0.14M
seekingalpha
2024-11-05
Beam Therapeutics press release (NASDAQ:BEAM): Q3 GAAP EPS of -$1.17 misses by $0.02.
Revenue of $14.27M (-17.0% Y/Y) beats by $0.14M.
Cash Position: Cash, cash equivalents and marketable securities were $925.8 million as of September 30, 2024, compared to $1.2 billion as of December 31, 2023.